Stephen Carey Net Worth

The estimated Net Worth of Stephen P. Carey is at least $12.9 Million dollars as of 4 June 2024. Mr. Carey owns over 5,000 units of ANI Pharmaceuticals Inc stock worth over $8,798,102 and over the last 9 years he sold ANIP stock worth over $1,910,843. In addition, he makes $2,156,390 as Corporate Secretary, Vice President, and Finance and Chief Financial Officer at ANI Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Carey ANIP stock SEC Form 4 insiders trading

Stephen has made over 3 trades of the ANI Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of ANIP stock worth $317,900 on 4 June 2024.

The largest trade he's ever made was selling 17,639 units of ANI Pharmaceuticals Inc stock on 14 August 2023 worth over $1,082,505. On average, Stephen trades about 951 units every 9 days since 2016. As of 4 June 2024 he still owns at least 161,968 units of ANI Pharmaceuticals Inc stock.

You can see the complete history of Mr. Carey stock trades at the bottom of the page.

Stephen Carey biography

Stephen P. Carey serves as Corporate Secretary, Vice President, Finance and Chief Financial Officer of the Company. From June 2007 to October 2015, Mr. Carey held various executive financial positions at Par Pharmaceutical Companies, Inc., including Senior Vice President, Controller and Principal Accounting Officer. Prior to that, Mr. Carey held various financial and accounting positions at Schering-Plough Corporation. Mr. Carey has over 25 years of experience as a financial executive, 20 of which are in the pharmaceutical industry. Mr. Carey began his career at PricewaterhouseCoopers. Mr. Carey graduated from Montclair State University with a B.S. degree in Accounting.

What is the salary of Stephen Carey?

As the Corporate Secretary, Vice President, and Finance and Chief Financial Officer of ANI Pharmaceuticals Inc, the total compensation of Stephen Carey at ANI Pharmaceuticals Inc is $2,156,390. There are 1 executives at ANI Pharmaceuticals Inc getting paid more, with Robert Schrepfer having the highest compensation of $2,160,980.

How old is Stephen Carey?

Stephen Carey is 50, he's been the Corporate Secretary, Vice President, and Finance and Chief Financial Officer of ANI Pharmaceuticals Inc since 2016. There are 10 older and 3 younger executives at ANI Pharmaceuticals Inc. The oldest executive at ANI Pharmaceuticals Inc is Thomas Penn, 73, who is the Independent Director.

What's Stephen Carey's mailing address?

Stephen's mailing address filed with the SEC is C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.

Insiders trading at ANI Pharmaceuticals Inc

Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri..., and Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.

What does ANI Pharmaceuticals Inc do?

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.

Complete history of Mr. Carey stock trades at ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc executives and stock owners

ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Robert Schrepfer,
  Senior Vice President - New Business Development and Specialty Sales
• Stephen Carey,
  Corporate Secretary, Vice President, Finance and Chief Financial Officer
• James Marken,
  Senior Vice President - Operations and Product Development
• James G. Marken,
  Sr. VP of Operations & Product Devel.
• Robert Brown,
  Independent Director
• Thomas Haughey,
  Independent Director
• Thomas Penn,
  Independent Director
• Patrick Walsh,
  Chairman of the Board
• David Nash,
  Independent Director
• Jeanne Thoma,
  Independent Director
• Antonio Pera,
  Independent Director
• Nikhil Lalwani,
  President, Chief Executive Officer, Director
• Muthasamy Shanmugam MS R.Ph.,
  Head of R&D and COO of Novitium Operations
• Ori Gutwerg,
  Sr. VP of Generics
• Christopher K. Mutz,
  Head of Rare Diseases
• Chad Gassert,
  Sr. VP of Corp. Devel. & Strategy
• Daniel Raynor,
  Director
• Arthur Przybyl,
  President and CEO
• Tracy Marshbanks,
  Director
• Fred Holubow,
  Director
• Peter A Lankau,
  Director
• Charlotte C. Arnold,
  Chief Financial Officer
• Renee P Tannenbaum,
  Director
• Ross J Mangano,
  Director
• Robert J. Jamnick,
  VP, Quality & Product Develop.
• Venture Partners Ii Lp Meri...,
  
• Ori Gutwerg,
  SVP, GENERICS
• Christopher Mutz,
  HEAD OF RARE DISEASE
• Krista Davis,
  SVP, CHIEF HR OFFICER
• Chad Gassert,
  SVP - CORP. DEV. & STRATEGY
• Meredith Cook,
  SR. VP, GENERAL COUNSEL & SEC.
• Muthusamy Shanmugam,
  HEAD OF R&D, COO-NOVITIUM OPS
• Matthew J Leonard,
  Director